Oligonucleotide (siRNA) · Gene silencing: apolipoprotein C-III (APOC3) · developed by Arrowhead
Plozasiran is a GalNAc-conjugated small interfering RNA that degrades apolipoprotein C-III mRNA through RNA interference, reducing hepatic and serum apoC-III protein levels. Lower apoC-III is associated with increased clearance of serum triglycerides. It is studied in hypertriglyceridemia, including severe hypertriglyceridemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06880770 | Phase 3 | Severe Hypertriglyceridemia | Recruiting | ARWR |
| NCT06822790 | Phase 3 | Hypertriglyceridemia | Active not recruiting | ARWR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HypertriglyceridemiaSevere Hypertriglyceridemia
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARWR page.
See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARWR catalysts and pipeline →